This website is intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk

Prescribing information can be found in the middle of the page and adverse event reporting information at the bottom of the page.

Oncology

Cancer is a major health burden in the UK. One in two people will get cancer in their lifetime,¹ and cancer has the highest impact on years of healthy life lost to premature mortality or disability of any disease.² At AstraZeneca, we are building on our deep-rooted oncology R&D heritage of nearly one hundred years in the UK, and continue to invest more than $5 billion per year in oncology R&D. Our relentless quest for innovation has led us to invest in a wide range of new potential medicines, novel tools including AI for improved diagnostics and novel treatment modalities including antibody drug conjugates, radioconjugates, T cell engagers and cell therapies, all of which will be required – and more – in order to progress towards our ambition of zero deaths from cancer.³

Our oncology focus areas

We are committed to improving treatment and research into several areas of oncology.

breats icon

Breast cancer is the most common cancer in the UK, with around 56,822 people diagnosed each year.^4,5 Breast cancer accounts for approximately 15% of all new cancer cases, and although survival rates have improved significantly over recent decades, breast cancer remains the leading cause of cancer death in women, with approximately 11,500 deaths each year.^4-6

There are several types of breast cancer, including both invasive and non-invasive types, with invasive carcinoma being the most prevalent.⁵ The risk of developing breast cancer increases with age, and about 80% of cases are diagnosed in women aged 50 and over.⁴

Due to ongoing advances in research, prevention, and early detection, ten-year survival rates have risen to over 75%.^5,6 However, with an ageing population, breast cancer incidence is projected to increase, with nearly 70,000 women being diagnosed each year by 2038-40.⁴

Explore AstraZeneca’s options for managing breast cancer:

LYNPARZA (olaparib)

LYNPARZA is indicated:

As monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.
As monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.

LYNPARZA (olaparib) Prescribing Information

TRUQAP▼ (capivasertib)

TRUQAP is indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (defined as IHC 0 or 1+, or IHC 2+/ISH–) locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine based regimen.

TRUQAP (capivasertib) Prescribing Information

FULVESTRANT Prescribing Information

Gastrointestinal icon

Approximately 70% of upper GI cancers in the UK are diagnosed at a late stage, when the disease is already unresectable or metastsatic and therefore significantly harder to manage than if detected earlier.⁷ Early symptoms are often non-specific, such as indigestion, and may be misattributed to benign conditions.⁸ This, alongside the lack of national screening programmes and regional inconsistencies in pathways post diagnosis,⁹ highlights a significant opportunity to optimise upper GI cancer pathways to enable earlier detection and better patient outcomes.

Biliary tract cancer is difficult to diagnose early, so it is often too advanced for surgery at diagnosis.¹⁰ As surgery is currently the only curative intervention, only 5% of people survive for five-years or more after diagnosis (2014-2016).¹¹

Explore AstraZeneca’s option for managing biliary tract cancer:

IMFINZI (durvalumab)

IMFINZI (durvalumab) in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer (BTC).

IMFINZI (durvalumab) Prescribing Information

Hepatocellular carcinoma mortality has risen fastest among the 20 most common UK cancers over the past decade.¹² Only 13% of people survive for ≥ five years from diagnosis, and just 40% survive for ≥ one year.^.13

Explore AstraZeneca's option for managing hepatobiliary carcinoma cancer:

IMFINZI (durvalumab) and IMJUDO▼ (tremelimumab)

IMFINZI (durvalumab) in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).

IMJUDO▼ (tremelimumab) in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).

IMFINZI (durvalumab) Prescribing Information

IMJUDO (tremelimumab) Prescribing Information

Gynaecological icon

In the UK, gynaecological and genitourinary cancers together account for more than 80,000 new diagnoses annually, with prostate cancer alone responsible for over 50,000 cases each year.^14,17

Despite improvements in care, outcomes remain poor for those with advanced disease: five-year survival rates across metastatic prostate, advanced bladder, advanced ovarian, and advanced endometrial cancers are below 50%.^18-21

These survival rates persist because current therapies may be limited by resistance, toxicity, short-lived responses, and the inability to address the underlying genetic and biological complexity of these cancers. As a result, many patients experience disease progression or relapse, with few options left to improve outcomes or maintain quality of life—highlighting an urgent unmet need for new treatments that are more targeted, longer-lasting, and better tolerated.²²

Explore AstraZeneca's option for managing muscle-invasive bladder cancer:

IMFINZI (durvalumab)

IMFINZI (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as monotherapy adjuvant treatment after radical cystectomy, is indicated for the treatment of adults with resectable muscle-invasive bladder cancer (MIBC) in the United Kingdom.

IMFINZI (durvalumab) Prescribing Information

Explore AstraZeneca's option for managing endometrial cancer:

IMFINZI (durvalumab) and LYNPARZA (olaparib)

IMFINZI in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by treatment with:

IMFINZI as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR).
IMFINZI in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).

LYNPARZA in combination with durvalumab is indicated for the maintenance treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair proficient (pMMR) whose disease has not progressed on first-line treatment with durvalumab in combination with carboplatin and paclitaxel.

IMFINZI (durvalumab) Prescribing Information

LYNPARZA (olaparib) Prescribing Information

Explore AstraZeneca's option for managing ovarian cancer:

LYNPARZA (olaparib)

LYNPARZA tablets are indicated as monotherapy for:

The maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA 1/2 -mutated (germline and/ or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
The maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

LYNPARZA in combination with bevacizumab is indicated for:

The maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA 1/2 mutation and/or genomic instability.

LYNPARZA (olaparib) Prescribing Information

Explore AstraZeneca's options for managing prostate cancer:

LYNPARZA (olaparib)

LYNPARZA is indicated:

As monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.
In combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated.

LYNPARZA (olaparib) Prescribing Information

ZOLADEX (goserelin)

ZOLADEX is indicated:

In the treatment of metastatic prostate cancer where ZOLADEX has demonstrated comparable survival benefits to surgical castrations.
In the treatment of locally advanced prostate cancer, as an alternative to surgical castration where ZOLADEX has demonstrated comparable survival benefits to an anti-androgen.
As adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer where ZOLADEX has demonstrated improved disease-free survival and overall survival.
As neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer where ZOLADEX has demonstrated improved disease-free survival.
As adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression where ZOLADEX has demonstrated improved disease-free survival.

ZOLADEX (goserelin) Prescribing Information

lung icon

Lung cancer is the most common cause of cancer death in the UK, accounting for 21% of all cancer deaths (2017-2019).²⁴ Lung cancer is broadly split into two types – non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).²⁵

Survival rates for lung cancer in the UK remain poorer than those in Europe.²⁷ In the UK, 40% of patients are first diagnosed during an emergency hospital admission.²⁶ Due to population growth and ageing, the absolute number of new cases of lung cancer is projected to rise, reaching approximately 66,200 annually by 2038–2040.²³

Explore AstraZeneca's options for managing lung cancer:

IMFINZI (durvalumab)

IMFINZI is indicated as monotherapy for:

the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy. Aligned with the ADRIATIC trial.
the treatment of locally advanced, unresectable NSCLC in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum‑based chemoradiation therapy. Aligned with the PACIFIC trial.

IMFINZI is indicated in combination with:

etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (ES‑SCLC). Aligned with the CASPIAN trial.
platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy after surgery, is indicated for the treatment of adults with resectable (tumours ≥ 4 cm and/or node positive) NSCLC and no known EGFR mutations or ALK rearrangements. Aligned with the AEGEAN trial.

IMFINZI (durvalumab) Prescribing Information

TAGRISSO (osimertinib)

TAGRISSO is indicated as monotherapy for:

the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. Aligned with the ADAURA trial.
the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy. Aligned with the LAURA trial.
the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations. Aligned with the FLAURA trial.
the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. Aligned with the AURA3 trial.

TAGRISSO is indicated in combination with:

pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) mutations. Aligned with the FLAURA-2 trial.

TAGRISSO (osimertinib) Prescribing Information

Other focus areas

Haematology

Our commitment to helping HCPs improve patient outcomes

At AstraZeneca, we are committed to accelerating progress across the cancer pathway in partnership with the NHS, health systems, and the wider cancer community to help:

Detect cancer earlier: expand and optimise screening and early detection, support risk-based and community-delivered pathways, and harness innovative diagnostics (including AI-enabled imaging and liquid biomarkers) to shift diagnoses to stages 1–2.
Advance equitable access: reduce unwarranted variation by improving uptake of screening and timely treatment in underserved groups, embedding equity-by-design in pathways and trials so outcomes improve irrespective of race, ethnicity, geography, or deprivation.
Personalise treatment: scale comprehensive biomarker and genomic testing, and enable timely access to precision medicines, novel combinations, and emerging modalities (e.g. antibody–drug conjugates, radioconjugates, T‑cell engagers), aligned to tumour biology.
Improve outcomes in less survivable cancers: prioritise earlier diagnosis, research, and fit‑for‑treatment pathways in cancers with persistently low survival, including faster access to trials and supportive care.
Leverage AI and data responsibly: support validated AI tools to reduce backlogs and enhance diagnostic accuracy, while ensuring robust governance, transparency, and representativeness to avoid widening inequalities.

We are supporting boundary‑pushing research and innovation across prevention, early detection, and treatment, informed by Cancer: Project Zero. Together with clinicians, patient groups, and system leaders, we aim to reframe practice toward earlier diagnosis, precision therapy, equitable access, and research‑enabled care – so more people live longer, better lives with and beyond cancer.

CRUK (2015) 1 in 2 people in the UK will get cancer. Available at: https://news.cancerresearchuk.org/2015/02/04/1-in-2-people-in-the-uk-will-get-cancer/ (Accessed May 2026).
Ahmad, A. S., Offman, J., Delon, C., North, B. V., Shelton, J., & Sasieni, P. D. (2023). Years of life lost due to cancer in the United Kingdom from 1988 to 2017. British journal of cancer, 129(10), 1558–1568. https://doi.org/10.1038/s41416-023-02422-8
Cancer: Project Zero (2024) The Essay Collection. Available at: https://www.astrazeneca.co.uk/content/dam/intelligentcontent/unbranded/astrazeneca/uk/en/pdf/articles/Cancer-Project-Zero-Summit-Complete-essay-compendium.pdf (Accessed May 2026)
Breast Cancer Now. Breast Cancer in the UK 2024. Available at: https://breastcancernow.org/media-assets/r4tfdgth/breast-cancer-in-the-uk-2024.pdf?_gl=1*uqspvi*_up*MQ..*_ga*MTcwNjc2MzI5Mi4xNzQxNjk1NDc4*_ga_F5D6D6WGJR*MTc0MTY5NTQ3OC4xLjAuMTc0MTY5NTQ3OC4wLjAuMA. (Accessed May 2026).
Rakha EA, Allison KH, Ellis IO, et al. Invasive carcinoma of no special type. In: WHO Classification of Tumours Editorial Board (eds). WHO Classification of Tumours, 5th edition, Breast Tumours. International Agency for Research on Cancer (IARC); 2019.
Cancer Research UK (2024) Breast cancer statistics. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer#breastcs0 (Accessed May 2026).
Cancer Research UK. Cancer statistics by type. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type. (Accessed May 2026)
NICE NG12 – Suspected cancer: recognition and referral. Available at: https://www.nice.org.uk/guidance/ng12. (Accessed May 2026)
NHS Cancer Screening – Overview. Available at: https://www.england.nhs.uk/cancer/early-diagnosis/screening-and-earlier-diagnosis/. (Accessed May 2026)
AMMF. Introduction to cholangiocarcinoma. Available at: https://ammf.org.uk/cholangiocarcinoma/. (Accessed May 2026)
Cancer Research UK. Survival for bile duct cancer. Available at: https://www.cancerresearchuk.org/about-cancer/bile-duct-cancer/survival. (Accessed May 2026)
Liver Cancer UK. Statistics about liver cancer. Available at: https://livercanceruk.org/liver-cancer-information/statistics/. (Accessed May 2026)
Liver Cancer UK. Liver Cancer: A call to action (2023). Available at: https://livercanceruk.org/wp-content/uploads/2023/10/LCUK-Report_SCREEN_Final-October-2023.pdf. (Accessed May 2026)
Cancer Research UK (2022). Prostate cancer statistics. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer#heading-One. (Accessed May 2026).
Cancer Research UK. Ovarian cancer statistics. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer#heading-Two. (Accessed May 2026).
Cancer Research UK. Uterine cancer incidence statistics. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/uterine-cancer/incidence#heading-Six. (Accessed May 2026).
Cancer Research UK (2022) Bladder cancer statistics. Available at:  https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bladder-cancer.(Accessed May 2026).
Prostate cancer survival: https://www.cancerresearchuk.org/about-cancer/prostate-cancer/survival%23:~:text=Around%252095%2520out%2520of%2520every,years%2520or%2520more%2520after%2520diagnosis. (Accessed May 2026).
Bladder cancer survival: Cancer Research UK. https://www.cancerresearchuk.org/about-cancer/bladder-cancer/survival. (Accessed May 2026).
Ovarian cancer survival: Cancer Research UK. https://www.cancerresearchuk.org/about-cancer/ovarian-cancer/survival. (Accessed May 2026).
Womb (endometrial) cancer survival: Cancer Research UK. https://www.cancerresearchuk.org/about-cancer/womb-cancer/survival. (Accessed May 2026).
Zafar et al (2025) Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy Discov. Oncol. 16:60
Cancer Research UK, Lung cancer statistics. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer. (Accessed May 2026).
Cancer Research UK. Lung cancer mortality statistics. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/mortality. (Accessed May 2026).
Cancer Research UK. Types of lung cancer. Available at: https://www.cancerresearchuk.org/about-cancer/lung-cancer/stages-types-grades/types. (Accessed May 2026).
ASCO Publications. Emergency diagnosis of lung cancer: An international problem. Available at: https://ascopubs.org/doi/10.1200/jco.2015.33.15_suppl.6536. (Accessed May 2026).
Newsom-Davis T. The route to diagnosis: emergency presentation of lung cancer. Lung Cancer Manag. 2017 Nov;6(2):67-73. doi: 10.2217/lmt-2017-0004. Epub 2017 Nov 17.

GB-74470 | May 2026

This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.

Cookie Policy

Oncology

Our oncology focus areas

Breast cancer

Gastrointestinal (GI) cancers

Gynaecological and Genitourinary cancers

Lung cancers

Other focus areas

Haematology

Our commitment to helping HCPs improve patient outcomes

Abbreviations and References